Skip to content

US · CVRX · MEDICAL - DEVICES

CVRx, Inc. (CVRX) intrinsic value and stock valuation

$0.50as of 2026-11-21 · Mkt cap 63.42M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CVRx, Inc. DCF and intrinsic value

InvestorsCraft values CVRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CVRX’s statements →

CVRx, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Minneapolis, MN 55445 cvrx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$56.7M+56.4% 5y CAGRd
20192025
Net income
-$-53.31M
20192025
Free cash flow
-$-40.75M
20192025
Total equity
$39.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$56.7M$51.3M$39.3M$22.5M$13M
Operating income-$-51.27M-$-59.49M-$-43.1M-$-42.53M-$-25.97M
Net income-$-53.31M-$-59.97M-$-41.2M-$-41.43M-$-43.08M
EPSd-$-2.04M-$-2.65M-$-1.99M-$-2.02M-$-2.08M
Operating cash flow-$-40.17M-$-39.14M-$-39.02M-$-42.68M-$-27.73M
Capital expenditure-$-580K-$-1.36M-$-590K-$-690K-$-1.18M
Free cash flow-$-40.75M-$-40.51M-$-39.61M-$-43.36M-$-28.91M
Total assets$104.8M$133.4M$115.2M$124.9M$152.6M
Total debt$50.8M$50.4M$30.6M$7.09M$0.00
Net debt-$-24.92M-$-55.5M-$-59.96M-$-99.11M-$-142.07M
Total equity$39.3M$71.1M$76M$109.2M$146M
Cash and short-term investments$75.7M$105.9M$90.6M$106.2M$142.1M
Income statement
20252024202320222021
Revenue$56.7M$51.3M$39.3M$22.5M$13M
Cost of revenue$8.31M$8.33M$6.26M$5M$3.64M
Gross profit$48.3M$43M$33M$17.5M$9.4M
Research and development expenses$11.1M$11.1M$11.6M$9.95M$7.5M
Selling, general and administrative expenses$88.5M$91.3M$64.5M$50.1M$27.9M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$99.6M$102.5M$76.1M$60M$35.4M
Cost and expenses$107.9M$110.8M$82.4M$65M$39M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$5.83M$4.4M$1.8M$170K$2.22M
Depreciation and amortization$760K$620K$520K$410K$170K
Ebitda-$-46.74M-$-54.89M-$-38.73M-$-40.74M-$-40.6M
Operating income-$-51.27M-$-59.49M-$-43.1M-$-42.53M-$-25.97M
Total other income/expenses, net-$-2.06M-$-420K$2.05M$1.21M-$-17.02M
Income before tax-$-53.32M-$-59.91M-$-41.05M-$-41.32M-$-42.99M
Income tax expense-$-20K$60K$150K$110K$90K
Net income-$-53.31M-$-59.97M-$-41.2M-$-41.43M-$-43.08M
Weighted average shares outstanding$26.1M$22.6M$20.7M$20.5M$20.7M
Weighted average diluted shares outstanding$26.1M$22.6M$20.8M$20.5M$20.7M
Balance sheet
20252024202320222021
Cash and short-term investments$75.7M$105.9M$90.6M$106.2M$142.1M
Net receivables$10.7M$9.27M$7.55M$5.5M$2.56M
Inventory$12.2M$12.1M$11M$6.96M$3.88M
Total current assets$101.7M$129.8M$112.1M$122.9M$151.1M
Property, plant and equipment, net$3.12M$3.57M$3.11M$2.03M$1.43M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$3.15M$3.6M$3.14M$2.06M$1.45M
Total assets$104.8M$133.4M$115.2M$124.9M$152.6M
Accounts payable$3.83M$2.58M$1.88M$1.72M$510K
Short-term debt$0.00$280K$230K$220K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$13.3M$10.8M$7.86M$8.09M$5.91M
Long-term debt$50.8M$50.2M$30.4M$6.86M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$52.2M$51.6M$31.4M$7.67M$680K
Capital lease obligations$640K$1.16M$1.39M$340K$0.00
Total liabilities$65.5M$62.4M$39.3M$15.8M$6.59M
Common stock$260K$250K$210K$210K$200K
Retained earnings-$-590.65M-$-537.35M-$-477.38M-$-436.18M-$-394.75M
Accumulated other comprehensive income (loss)-$-200K-$-210K-$-210K-$-210K-$-200K
Total equity$39.3M$71.1M$76M$109.2M$146M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$50.8M$50.4M$30.6M$7.09M$0.00
Net debt-$-24.92M-$-55.5M-$-59.96M-$-99.11M-$-142.07M
Cash flow statement
20252024202320222021
Net income-$-53.31M-$-59.97M-$-41.2M-$-41.43M-$-43.08M
Depreciation and amortization$760K$620K$520K$410K$170K
Stock-based compensation$11.1M$19.1M$6.3M$3.89M$1.91M
Change in working capital$1M$950K-$-4.8M-$-5.57M-$-1.58M
Accounts receivable-$-1.4M-$-1.72M-$-2.05M-$-2.94M-$-1.28M
Inventory-$-100K-$-1.12M-$-4.03M-$-3.08M-$-540K
Accounts payable$1.25M$700K$170K$1.21M$30K
Net cash provided by operating activities-$-40.17M-$-39.14M-$-39.02M-$-42.68M-$-27.73M
Investments in property, plant and equipment-$-580K-$-1.36M-$-590K-$-690K-$-1.18M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-580K-$-1.36M-$-590K-$-690K-$-1.18M
Common stock issued$10.5M$32.5M$1.66M$770K$133.2M
Common stock repurchased$0.00$0.00$0.00$0.00-$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.5M$55.9M$24M$7.49M$111.9M
Net change in cash-$-30.23M$15.4M-$-15.62M-$-35.88M$83M
Cash at end of period$75.7M$105.9M$90.6M$106.2M$142.1M
Operating cash flow-$-40.17M-$-39.14M-$-39.02M-$-42.68M-$-27.73M
Capital expenditure-$-580K-$-1.36M-$-590K-$-690K-$-1.18M
Free cash flow-$-40.75M-$-40.51M-$-39.61M-$-43.36M-$-28.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CVRx, Inc.

        CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

        CEO
        Kevin Hykes
        Employees
        223
        Beta
        0.78

        Explore

        Frequently asked questions

        What is the intrinsic value of CVRx, Inc. (CVRX)?

        InvestorsCraft does not currently publish an intrinsic value for CVRX. How the IC value is calculated.

        Is CVRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for CVRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.